Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment

Pancreatic cancer (PC) is one of the most common malignancies and also a leading cause of cancer-related mortality worldwide. Many studies have shown that epidermal growth factor receptor (EGFR) is highly expressed in PC, which provides a potential target for PC treatment. However, EGFR inhibitors u...

Full description

Bibliographic Details
Main Authors: Shihui Bao, Hailun Zheng, Jinyao Ye, Huirong Huang, Bin Zhou, Qing Yao, Guangyong Lin, Hailin Zhang, Longfa Kou, Ruijie Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
nanoparticles
STAT3
EGFR
synergistic effect
pancreatic cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.625084/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.625084/full

Similar Items